Case Study: Leading Life Sciences Companies improve outcomes and reduce costs with EXL HEOR solution

Comparing total cost of care and outcomes for drugs that treat rheumatoid arthritis and several other chronic conditions

EXL worked with a leading life sciences company that needed to compare the total cost of care and outcomes for patients using its rheumatoid arthritis drug across multiple indications, including against alternate therapies, non-biologic drugs, combination biologic therapies, and no treatment. The customer wanted to protect the drug’s strong market position while building evidence to support value-based care and payer negotiations.

Using EXL’s Health Economics and Outcomes Research (HEOR) solution, the company analyzed real-world data on costs, utilization, and adherence across Commercial and Medicare populations. EXL helped identify where costs were highest, which patient groups used the therapy most, and where adherence was strongest, enabling the life sciences company to highlight the drug’s clinical and financial value, sustain market leadership, and negotiate more favorable value-based contracts with payers.